Alexion Pharmaceuticals Inc (ALXN.OQ)
|Market Cap (Mil.):||$35,609.47|
|Shares Outstanding (Mil.):||197.83|
- Alexion Pharmaceuticals Inc raised its profit and sales forecast for the year after the French government agreed to raise reimbursement payments for the company's treatment for two rare blood disorders.
* Decision should help reimbursement talks in Spain, Italy-analyst
March 10 - Alexion Pharmaceuticals Inc revised its profit and sales outlook for the year after the French government agreed to raise reimbursement payments for the company's lead drug, Soliris.
LONDON, March 4 - Britain's healthcare costs watchdog has asked U.S. biotech group Alexion Pharmaceuticals to explain the high price for its Soliris drug before deciding whether the treatment should be paid for by the state health service.
- Shares of Alexion Pharmaceuticals Inc soared 27 percent to a life-high after the company forecast $2 billion in sales for its blood disorder drug this year ahead of analysts' average estimate.
(Adds details from conference call, analysts' comments; updates share movement)
Jan 30 - Alexion Pharmaceuticals Inc said it expected revenue from its blood disorder drug, Soliris, to hit the $2 billion mark in 2014, sending its shares up 27 percent to a life-high.
* Will follow drug needs, no matter for how many patients - CEO
Earnings vs. Estimates
Analyst Research Reports
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report
Provider: Wright Reports
Provider: S&P Capital IQ – STARS Reports
Alexion Pharmaceuticals Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile